Skip to main content
PMC home page
Springer logoLink to Springer
. 2020 Oct 28;53(3):523–530. doi: 10.1007/s11255-020-02651-3

The prognostic value of platelet-to-lymphocyte ratio on the long-term renal survival in patients with IgA nephropathy

Dan Chang 1,2,#, Yichun Cheng 2,#, Ran Luo 2, Chunxiu Zhang 2, Meiying Zuo 2, Yulin Xu 2, Wei Dai 2, Yueqiang Li 2, Min Han 2, Xiaofeng He 2, Shuwang Ge 2,✉, Gang Xu 2,✉
PMCID: PMC7906929  PMID: 33113085

Abstract

Purpose

Platelet-to-lymphocyte ratio (PLR) was established showing the poor prognosis in several diseases, such as malignancies and cardiovascular diseases. But limited study has been conducted about the prognostic value of PLR on the long-term renal survival of patients with Immunoglobulin A nephropathy (IgAN).

Methods

We performed an observational cohort study enrolling patients with biopsy-proven IgAN recorded from November 2011 to March 2016. The definition of composite endpoint was eGFR decrease by 50%, eGFR < 15 mL/min/1.73 m2, initiation of dialysis, or renal transplantation. Patients were categorized by the magnitude of PLR tertiles into three groups. The Kaplan–Meier curves and multivariate Cox models were performed to determine the association of PLR with the renal survival of IgAN patients.

Results

330 patients with a median age of 34.0 years were followed for a median of 47.4 months, and 27 patients (8.2%) had reached the composite endpoints. There were no differences among the three groups (PLR < 106, 106 ≤ PLR ≤ 137, and PLR > 137) in demographic characteristics, mean arterial pressure (MAP), proteinuria, and estimated glomerular filtration rate (eGFR) at baseline. The Kaplan–Meier curves showed that the PLR > 137 group was significantly more likely to poor renal outcomes than the other two groups. Using univariate and multivariate cox regression analyses, we found that PLR > 137 was an independent prognostic factor for poor renal survival in patients with IgAN. Subgroup analysis revealed that the PLR remained the prognostic value for female patients or patients with eGFR less than 60 mL/min/1.73 m2.

Conclusions

Our results underscored that baseline PLR was an independent prognostic factor for poor renal survival in patients with IgAN, especially for female patients or those patients with baseline eGFR less than 60 mL/min/1.73 m2.

Keywords: Immunoglobulin A nephropathy, Platelet-to-lymphocyte ratio, Renal survival, Cohort

Introduction

Immunoglobulin A nephropathy (IgAN) is one of the most common primary glomerulonephritis worldwide [1]. The number of patients with IgAN accounts for 58.2% of glomerulonephritis in China [2]. Studies have shown that 15% to 40% of patients with IgAN develop the end-stage renal disease (ESRD) by 10 to 20 years after diagnosis [3, 4]. As one of the main reasons to increase the social burden, however, it is still challenging to precisely predict the outcomes of IgAN patients [5, 6]. Several clinical indicators such as renal function and proteinuria at biopsy are demonstrated to be associated with the renal outcome of IgAN [7–9]. But we need to find new risk factors of IgAN to timely prevent the disease from deterioration.

Platelet-to-lymphocyte ratio (PLR), calculated as platelet count divided by the lymphocyte count, is an inexpensive, replicable, and easily measurable index. There is increasing evidence suggesting that PLR may serve as a novel inflammatory marker and prognostic factors for various diseases, such as malignancies [10–13], cardiovascular diseases [14, 15], chronic obstructive pulmonary disease [16] and saphenous vein graft disease [17].

Although the pathogenesis of IgAN is not completely understood, multiple mechanisms may be involved, and inflammation is known to play a key role [18–21]. However, the clinical significance of PLR in the IgAN process remains unclear. Hence, we conducted this study to explore the prognostic value of PLR on long-term renal survival among patients with IgAN.

Materials and methods

Study design and study population

Three hundred and thirty patients with IgAN were recruited in the Tongji hospital affiliated to Tongji medical college of Huazhong University of Science and Technology from November 1, 2011, to March 1, 2016 (Fig. 1). We included biopsy-proven IgAN patients with complete clinical and pathological data. And we excluded patients with blood system disease, connective tissue disease, active infection, and baseline eGFR less than 30 mL/min/1.73 m2. Patients who received immunosuppressant, glucocorticoid, or nonsteroidal anti-inflammatory drugs treatment at the time of renal biopsy were also excluded.

Fig. 1.

Fig. 1

Open in a new tab

Flow chart of the patients included in the study

Demographic and clinical data

Baseline demographic, clinical and laboratory data were collected from all patients at the time of renal biopsy, including age, gender, systolic blood pressure (SBP), diastolic blood pressure (DBP), white blood cell count (WBC), platelet count, lymphocyte count, hemoglobin, serum albumin, serum creatinine (Scr), uric acid (UA), estimated glomerular filtration rate (eGFR), and proteinuria quantity.

PLR was calculated as the ratio of the absolute platelet count to the absolute lymphocyte count on preoperative routine blood tests.

The blood pressure of patients was measured by a cuff pressure method using a mercury sphygmomanometer or an electronic sphygmomanometer. Mean arterial pressure (MAP) was calculated by (SBP + 2 × DBP)/3.

eGFR is calculated by the Modification of Diet in Renal Disease Study (MDRD) equation: 186 × (Creatinine/88.4)−1.154 × (Age)−0.203 × (0.742 if female) × (1.210 if black) [22].

Regular visits at intervals of 6 months were performed in every patient. Urine sediment and renal function were tested at every visit throughout follow-up. All follow-up data were updated to March 1, 2019.

Study outcomes

For survival analysis, the definition of composite endpoint was eGFR decrease by 50% or ESRD. ESRD was defined as eGFR < 15 mL/min/1.73 m2, initiation of dialysis, or renal transplantation. Patients were censored at the time of endpoint or loss of follow-up.

Statistical analysis

The distributions of quantitative variables were assessed for normality. Continuous variables were expressed as the mean ± standard deviation (SD) (normally distributed variables) or median and interquartile range (IQR) (non-normally distributed variables). For continuous data, one-way analysis of variance was used if the variable was normally distributed; if not, Kruskal–Wallis tests were performed. Categorical data were expressed as frequencies and percentages (%) and compared by Pearson chi-squared tests or Fisher’s exact test, as appropriate. The probabilities of cumulative renal survival curves were generated by the Kaplan–Meier method, and the differences between curves were analyzed by a log-rank test. Univariate and multivariate Cox regression proportional hazards models were built to evaluate independent risk factors of renal progression. No violations of the Cox proportional hazards assumptions were detected. The results of Cox regression analyses were expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). P values ≤ 0.05 were considered to indicate statistical significance with 95% CIs. Statistical Package for the Social Sciences (version 22.0, 2013, IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp) and R software (version 3.5.1, 2013, R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/) were used for all statistical analyses.

Results

The main characteristics of the included patients are shown in Table 1. A total of 330 cases were enrolled in this study, including 137 (41.5%) men and 193 (58.5%) women with a median age of 34.0 years and a median PLR of 120.4. Patients were followed for a median of 47.4 months.

Table 1.

Clinical characteristics at the time of renal biopsy and outcomes of included patients categorized by the magnitude of PLR tertiles

Variables All PLR < 106 106 ≤ PLR ≤ 137 PLR > 137 P-value Test statistic
At the time of renal biopsy
Number of patients (n) 330 111 109 110
Age (years, median [IQR]) 34.0 [15] 36.0 [16] 34.0 [15] 33.0 [16] 0.598 1.030a
Male (n, %) 137(41.5) 49 (44.1) 44 (40.4) 44 (40.0) 0.787 0.479b
MAP (mmHg, mean (SD)) 97.8 (13.7) 96.6 (14.1) 98.3 (13.1) 98.5 (13.9) 0.542 0.613c
WBC (× 109/L, median [IQR]) 6.79 [2.39] 7.06 [2.57] 6.79 [2.28] 6.34 [2.51] 0.163 3.624a
Lymphocytes (× 109/L, median [IQR]) 1.84 [0.75] 2.27 [0.70] 1.88 [0.55] 1.54 [0.51]  < 0.001 89.433a
Platelets (× 109/L, median [IQR]) 222.0 [83.5] 187.0 [77.0] 225.0 [73.0] 252.0 [77.2]  < 0.001 60.560a
Hemoglobin (g/L, mean (SD)) 130.9 (20.2) 132.2 (18.2) 131.7 (21.7) 128.8 (20.5) 0.392 0.940c
Serum albumin (g/l, mean (SD)) 39.3 (5.7) 39.8 (4.5) 39.3 (5.7) 38.9 (6.7) 0.440 0.869c
Scr (μmol/L, median [IQR]) 83.5 [42.0] 83.0 [41.0] 86.0 [42.5] 82.0 [47.3] 0.799 0.449a
UA (μmol/L, mean (SD)) 356.2 (99.2) 359.2 (90.4) 352.0 (94.6) 357.3 (112.2) 0.858 0.172c
eGFR (ml/min/1.73 m2, median [IQR]) 89.5 [47.5] 92.6 [45.2] 83.7 [45.7] 88.9 [55.6] 0.778 0.503a
Proteinuria (g/24 h, median [IQR]) 0.78 [1.34] 0.96 [1.00] 1.03 [1.52] 0.63 [1.57] 0.209 3.135a
Follow-up and treatment
Follow-up (months, median [IQR]) 47.4 [24.0] 49.6 [23.2] 49.1 [25.6] 43.9 [20.3] 0.016 8.332a
Composite endpoints (n, %) 27 (8.2) 6 (5.4) 6 (5.5) 15 (13.6) 0.038 6.535b
ESRD (n, %) 10 (3.0) 2 (1.8) 0 (0.0) 8 (7.3) 0.003 9.663b
Use of RAAS blockade (n, %) 151 (45.8) 48 (43.2) 57 (52.3) 46 (41.8) 0.241 2.847b
Use of IS (n, %) 236 (71.5) 76 (68.5) 80 (73.4) 80 (72.7) 0.679 0.774b
Open in a new tab

PLR platelet-to-lymphocyte ratio, IQR interquartile range, SD standard deviation, MAP mean arterial pressure, WBC white blood cell co nt, Scr serum creatinine, UA uric acid, eGFR estimated glomerular filtration rate, RAAS rein-angiotensin-aldosterone-system, IS immune suppression. Composite endpoint was eGFR decrease by 50% or ESRD. ESRD was defined as eGFR < 15 mL/min/1.73 m2, initiation of dialysis or renal transplantation

aTest statistic value for Kruskal–Wallis test (for non-normally distributed continuous data)

bChi-square value for standard chi-squared test or Fisher’s exact test (for categorical data)

cF-ratio value for one-way ANOVA (normally distributed continuous data)

Patients were categorized by the magnitude of PLR tertiles into three groups: group 1 with PLR < 106 (n = 111), group 2 with 106 ≤ PLR ≤ 137 (n = 109) while group 3 with PLR > 137 (n = 110) (Table 1). There were no significant differences among the three groups in demographic characteristics, MAP, proteinuria, and renal function at baseline. And No significant differences were found among the three groups in the use of rein-angiotensin-aldosterone-system (RAAS) blockade and immune suppression (IS) treatments. Patients with higher PLR value had higher platelet count and lower lymphocyte count. There were 2 (0.6%) patients with a low level of platelet (< 100 × 109/L) and 30 (9.1%) patients with a high level of platelet (> 300 × 109/L). At the end of follow-up, 27 patients (8.2%) had reached the composite endpoints, including 17 patients with eGFR decrease by 50% and 10 patients with ESRD.

The Kaplan–Meier curve showed the association of PLR with poor renal outcomes among IgAN patients (Fig. 2). As no significant difference in the Kaplan–Meier curve was seen between the first and the second tertile of the PLR group, we put the two groups together as PLR ≤ 137 group. Univariate analysis by Cox regression revealed that hemoglobin, serum albumin, Scr, UA, eGFR, and proteinuria at the time of renal biopsy and use of IS treatments were factors significantly associated with renal survival, which was defined by a status free of composite endpoints (Table 2). Besides, the lymphocyte count and platelet count were not associated with poor renal outcomes. When compared with group PLR ≤ 137, PLR > 137 was associated with a higher risk (HR 3.10; 95% CI 1.44–6.64; P = 0.004) of experiencing the poor renal outcomes. Moreover, after adjusted for age, sex, hemoglobin, serum albumin, Scr, UA, eGFR, proteinuria, and use of IS treatments, PLR > 137 (HR 2.79; 95% CI 1.08–7.26; P = 0.035) was still associated with poor renal outcomes among IgAN patients compared with PLR ≤ 137 (Table 3).

Fig. 2.

Fig. 2

Open in a new tab

Renal survival curves for the patients with IgAN according to the platelet-to-lymphocyte ratio

Table 2.

Univariate Cox regression analyses of renal survival in patients with IgAN

Risk factor Univariate
HR 95% CI P-value
Age, years 1.00 0.96–1.04 0.962
Male 1.41 0.66–3.00 0.376
MAP, mmHg 1.02 0.99–1.05 0.128
WBC, × 109/L 0.98 0.83–1.16 0.806
Lymphocytes, × 109/L 0.57 0.28–1.19 0.134
Platelets, × 109/L 1.00 0.99–1.01 0.471
PLR > 137 3.10 1.44–6.64 0.004
Hemoglobin, g/L 0.97 0.95–0.99 0.001
Serum albumin, g/l 0.92 0.88–0.97 0.001
Scr, μmol/L 1.04 1.03–1.05  < 0.001
UA, μmol/L 1.01 1.00–1.01  < 0.001
eGFR, ml/min/1.73 m2 0.92 0.90–0.95  < 0.001
Proteinuria, g/24 h 1.38 1.16–1.63  < 0.001
Use of RAAS blockade 0.59 0.27–1.30 0.190
Use of IS 0.23 0.11–0.51  < 0.001
Open in a new tab

IgAN Immunoglobulin A nephropathy, HRs hazard ratios, CIs confidence intervals, PLR platelet-to-lymphocyte ratio, MAP mean arterial pressure, WBC white blood cell count, Scr serum creatinine, UA uric acid, eGFR estimated glomerular filtration rate, RAAS rein-angiotensin-aldosterone-system, IS immune suppression

Table 3.

Multivariate Cox regression analyses of renal survival in patients with IgAN

Risk factor Multivariate
HR 95% CI P-value
Age, years 0.93 0.88–0.99 0.019
Male 0.67 0.13–1.01 0.637
PLR > 137 2.79 1.08–7.26 0.035
Hemoglobin, g/L 0.98 0.96–1.01 0.199
Serum albumin, g/l 0.97 0.89–1.07 0.582
Scr, μmol/L 1.00 0.95–1.05 0.962
UA, μmol/L 1.00 1.00–1.01 0.925
eGFR, ml/min/1.73 m2 0.94 0.87–1.02 0.131
Proteinuria, g/24 h 1.20 0.86–1.68 0.284
Use of IS 0.17 0.06–0.52 0.002
Open in a new tab

IgAN Immunoglobulin A nephropathy, HRs hazard ratios, CIs confidence intervals, PLR platelet-to-lymphocyte ratio, Scr serum creatinine, UA uric acid, eGFR estimated glomerular filtration rate, IS immune suppression

To be more precise, we also analyzed the renal survival of patients according to the sex, baseline eGFR, and proteinuria categories. As shown in Fig. 3, among female patients, PLR > 137 was associated with poor renal outcomes compared with PLR ≤ 137 after adjusted for age, hemoglobin, serum albumin, Scr, UA, eGFR, proteinuria, and use of IS treatments. We also found that patients with baseline eGFR lower than 60 mL/min/1.73 m2 had a significantly better renal survival in patients with PLR ≤ 137 than PLR > 137. While no significant difference was observed between PLR ≤ 137 and PLR > 137 groups in male patients or patients whose baseline eGFR higher than 60 mL/min/1.73 m2, baseline proteinuria higher than 1 g/24 h or lower than 1 g/24 h.

Fig. 3.

Fig. 3

Open in a new tab

Subgroup analyses about the association of platelet-to-lymphocyte ratio and renal survival according to sex, baseline eGFR, and baseline proteinuria for the patients with IgAN

Discussion

Although the platelet count and lymphocyte count are routinely evaluated under simple laboratory conditions among the patients with IgAN, the clinical significance of PLR in the IgAN process remains unclear. Our study evaluated the relationship between PLR and the renal regression of IgAN and demonstrated that PLR > 137 were independent prognostic factors for the long-term renal survival of patients with IgAN.

The advantage of the PLR is that it reflects the condition of patients in both inflammation and thrombosis pathways. It may be more valuable than either platelet or lymphocyte count alone. In our study, the mean value and corresponding 95% reference interval for the PLR in IgAN patients was 125.8 (63.3–227.9), which was close to the PLR value in the general population reported in a population-based prospective cohort study: 120 (61–239) [23]. Most studies showed that elevated PLR value played a predictive role in several diseases [12, 24–27]. Our study found the same outcomes in IgAN. As we all know, platelets and lymphocytes are derived from the same hematopoietic stem cells and the PLR should be kept constant for homeostasis [28, 29]. Higher PLR condition means relatively high platelets and low lymphocytes. Higher platelet count may reflect increased thrombocyte activation, which contributes to increased inflammation and thrombocytosis, and thereby result in adverse renal outcomes [30, 31]. Lymphocytopenia, which reveals depression of innate cellular immunity, may be induced by the systemic inflammatory response, and be responsible for an inadequate immunologic reaction and a weakened defense [32, 33]. Considering platelets and lymphocytes together, an elevated PLR might predict the bad body condition and weakening inflammatory response in those IgAN patients with poorer renal outcomes.

After Stratified analysis, we also found that the prognostic value of PLR remained the same for female patients or patients with eGFR less than 60 mL/min/1.73 m2. As we all know, females tend to mount stronger inflammatory responses than males [34–38], so the inflammation indicator, PLR, was more sensitive in female patients with IgAN. And for those IgAN patients with eGFR less than 60 mL/min/1.73 m2, they may have increased serum levels of inflammatory mediators and were more susceptible to inflammation-related vascular dysfunction and cardiovascular risk compared with healthy controls [39, 40]. Turkmen et al. [24] carried out a cross-sectional study involving 62 ESRD patients prompted that a simple calculation of PLR can predict inflammation in ESRD patients. These may suggest that those IgAN patients with worse renal function have been in a long-term inflammatory state, so the inflammation factors occupy a larger proportion in the progression to renal failure.

Besides the PLR, hemoglobin, serum albumin, Scr, UA, eGFR, proteinuria, and use of IS treatments were also factors significantly associated with renal survival in the present study. Several clinical indicators such as renal function and proteinuria at biopsy are demonstrated to be associated with the renal outcome of IgAN [7–9, 41, 42]. Our study also found that the use of IS therapy was associated with better renal outcomes among IgAN patients. IS therapy was a common treatment for immune-mediated kidney disease, however, the role of the use of IS therapy in IgAN was still controversial [43–47]. Larger prospective studies with more patients and longer follow-up time were needed to assess the effect of IS therapy in IgAN.

This study had several limitations. The potential limitation of the present study was that it was a retrospective, single-center study with a relatively small sample size of patients and a low number of endpoints reached. Thus, larger prospective studies, multi-site studies with patients of various ethnicities are needed to confirm these preliminary results. Another limitation was that we measured the blood pressure with two different devices with two different measurement errors. Due to the nature of the retrospective cohort study, we are not able to remeasure the blood pressure and recollect information which might result in recall or misclassification bias. Also, besides PLR, there were some other markers of inflammation, such as CRP, serum iron, ferritin [48], which should be tested and taken into consideration in our future study.

In conclusion, we demonstrated that PLR > 137 was independent prognostic factors for the long-term renal survival of IgAN. Clinicians can pay more attention to the PLR value in the management of IgAN patients, especially for those female patients or whose eGFR lower than 60 mL/min/1.73 m2.

Abbreviations

PLR

Platelet-to-lymphocyte ratio

IgAN

Immunoglobulin A nephropathy

ESRD

End-stage renal disease

SBP

Systolic blood pressure

DBP

Diastolic blood pressure

MAP

Mean arterial pressure

WBC

White blood cell count

Scr

Serum creatinine

UA

Uric acid

eGFR

Estimated glomerular filtration rate

MDRD

Modification of Diet in Renal Disease Study

SD

Standard deviation

IQR

Interquartile range

HRs

Hazard ratios

CIs

Confidence intervals

RAAS

Rein-angiotensin-aldosterone-system

IS

Immune suppression

Funding

This work was financially supported by Major Research Plan of the National Natural Science Foundation of China (Grant No. 91742204, 81470948, 81670633, 81570667), International (regional) cooperation and exchange projects, (NSFC-DFG, Grant No. 81761138041), National key research and development program (Grants 2016YFC0906103, 2013BAI09B06, 2015BAI12B07).

Compliance with ethical standards

Conflict of interest

Authors of this study have no conflict of interest.

Ethical approval

This is an observational study approved by the Medical Ethics Committee of the Tongji Hospital Affiliated with Tongji Medical College, Huazhong University of Science and Technology (approval number TJ-IRB20181108). All study procedures complied with the Declaration of Helsinki. All patients provided written informed consent to participate in the study.

Informed consent

This study was performed after obtaining written informed consent from all patients.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Dan Chang and Yichun Cheng contributed equally to this work.

Contributor Information

Shuwang Ge, Email: geshuwang@tjh.tjmu.edu.cn.

Gang Xu, Email: xugang@tjh.tjmu.edu.cn.

References

  • 1.Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402–2414. doi: 10.1056/NEJMra1206793. [DOI] [PubMed] [Google Scholar]
  • 2.Yeo SC, Goh SM, Barratt J. Is immunoglobulin A nephropathy different in different ethnic populations? Nephrology (Carlton) 2019;24(9):885–895. doi: 10.1111/nep.13592. [DOI] [PubMed] [Google Scholar]
  • 3.Barbour SJ, Cattran DC, Kim SJ, et al. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int. 2013;84(5):1017–1024. doi: 10.1038/ki.2013.210. [DOI] [PubMed] [Google Scholar]
  • 4.Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004;66(3):920–923. doi: 10.1111/j.1523-1755.2004.00837.x. [DOI] [PubMed] [Google Scholar]
  • 5.Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709–733. doi: 10.1016/S0140-6736(20)30045-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Schena FP, Cox SN. Biomarkers and precision medicine in IgA nephropathy. Semin Nephrol. 2018;38(5):521–530. doi: 10.1016/j.semnephrol.2018.05.022. [DOI] [PubMed] [Google Scholar]
  • 7.Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. Am J Kidney Dis. 2012;59(6):865–873. doi: 10.1053/j.ajkd.2012.02.326. [DOI] [PubMed] [Google Scholar]
  • 8.Barbour S, Reich H. An update on predicting renal progression in IgA nephropathy. Curr Opin Nephrol Hypertens. 2018;27(3):214–220. doi: 10.1097/MNH.0000000000000405. [DOI] [PubMed] [Google Scholar]
  • 9.Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27(4):1479–1485. doi: 10.1093/ndt/gfr527. [DOI] [PubMed] [Google Scholar]
  • 10.Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prevent. 2014;23(7):1204–1212. doi: 10.1158/1055-9965.EPI-14-0146. [DOI] [PubMed] [Google Scholar]
  • 11.Li DY, Hao XY, Ma TM, Dai HX, Song YS. The prognostic value of platelet-to-lymphocyte ratio in urological cancers: a meta-analysis. Sci Rep. 2017;7(1):15387. doi: 10.1038/s41598-017-15673-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Wang J, Liu Y, Zhang N, et al. Prognostic role of pretreatment platelet to lymphocyte ratio in urologic cancer. Oncotarget. 2017;8(41):70874–70882. doi: 10.18632/oncotarget.20147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wang Z, Peng S, Wang A, et al. Platelet-lymphocyte ratio acts as an independent predictor of prognosis in patients with renal cell carcinoma. Clin Chim Acta. 2018;480:166–172. doi: 10.1016/j.cca.2018.02.014. [DOI] [PubMed] [Google Scholar]
  • 14.Sun XP, Li J, Zhu WW, et al. Impact of platelet-to-lymphocyte ratio on clinical outcomes in patients with ST-segment elevation myocardial infarction. Angiology. 2017;68(4):346–353. doi: 10.1177/0003319716657258. [DOI] [PubMed] [Google Scholar]
  • 15.Lee YSG, Baradi A, Peverelle M, et al. Usefulness of platelet-to-lymphocyte ratio to predict long-term all-cause mortality in patients at high risk of coronary artery disease who underwent coronary angiography. Am J Cardiol. 2018;121(9):1021–1026. doi: 10.1016/j.amjcard.2018.01.018. [DOI] [PubMed] [Google Scholar]
  • 16.Yao C, Liu X, Tang Z. Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD. Int J Chronic Obstr Pulm Dis. 2017;12:2285–2290. doi: 10.2147/COPD.S141760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Cerit L. Platelet to lymphocyte ratio and saphenous vein graft disease. Angiology. 2017;68(3):29. doi: 10.1177/0003319716668772. [DOI] [PubMed] [Google Scholar]
  • 18.Rollino C, Vischini G, Coppo R. IgA nephropathy and infections. J Nephrol. 2016;29(4):463–468. doi: 10.1007/s40620-016-0265-x. [DOI] [PubMed] [Google Scholar]
  • 19.Sakai H. Cellular immunoregulatory aspects of IgA nephropathy. Am J Kidney Dis. 1988;12(5):430–432. doi: 10.1016/s0272-6386(88)80040-4. [DOI] [PubMed] [Google Scholar]
  • 20.Rauen T, Floege J. Inflammation in IgA nephropathy. Pediatr Nephrol. 2017;32(12):2215–2224. doi: 10.1007/s00467-017-3628-1. [DOI] [PubMed] [Google Scholar]
  • 21.Wang J, Anders RA, Wu Q, et al. Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. J Clin Invest. 2004;113(6):826–835. doi: 10.1172/JCI20096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470. doi: 10.7326/0003-4819-130-6-199903160-00002. [DOI] [PubMed] [Google Scholar]
  • 23.Fest J, Ruiter R, Ikram MA, et al. Reference values for white blood-cell-based inflammatory markers in the Rotterdam Study: a population-based prospective cohort study. Sci Rep. 2018;8(1):10566. doi: 10.1038/s41598-018-28646-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Turkmen K, Erdur FM, Ozcicek F, et al. Platelet-to-lymphocyte ratio better predicts inflammation than neutrophil-to-lymphocyte ratio in end-stage renal disease patients. Hemodial Int. 2013;17(3):391–396. doi: 10.1111/hdi.12040. [DOI] [PubMed] [Google Scholar]
  • 25.Cao W, Yao X, Cen D, et al. The prognostic role of platelet-to-lymphocyte ratio on overall survival in gastric cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2020;20(1):16. doi: 10.1186/s12876-020-1167-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Bao Y, Wang Y, Li X, et al. Prognostic significance of platelet-to-lymphocyte ratio in urothelial carcinoma patients: a meta-analysis. Cancer Cell Int. 2019;19:315. doi: 10.1186/s12935-019-1032-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Tsai SF, Wu MJ, Wen MC, Chen CH. Serologic and histologic predictors of long-term renal outcome in biopsy-confirmed IgA nephropathy (Haas Classification): an observational study. J Clin Med. 2019;8(6):848. doi: 10.3390/jcm8060848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Dharampuriya PR, Scapin G, Wong C, et al. Tracking the origin, development, and differentiation of hematopoietic stem cells. Curr Opin Cell Biol. 2017;49:108–115. doi: 10.1016/j.ceb.2018.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell. 2008;132(4):631–644. doi: 10.1016/j.cell.2008.01.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Akkaya E, Gul M, Ugur M. Platelet to lymphocyte ratio: a simple and valuable prognostic marker for acute coronary syndrome. Int J Cardiol. 2014;177(2):597–598. doi: 10.1016/j.ijcard.2014.08.143. [DOI] [PubMed] [Google Scholar]
  • 31.Balta S, Demırkol S, Kucuk U. The platelet lymphocyte ratio may be useful inflammatory indicator in clinical practice. Hemodial Int. 2013;17(4):668–669. doi: 10.1111/hdi.12058. [DOI] [PubMed] [Google Scholar]
  • 32.Egido J, Blasco R, Sancho J, Lozano L. T-cell dysfunctions in IgA nephropathy: specific abnormalities in the regulation of IgA synthesis. Clin Immunol Immunopathol. 1983;26(2):201–212. doi: 10.1016/0090-1229(83)90138-1. [DOI] [PubMed] [Google Scholar]
  • 33.Menges T, Engel J, Welters I, et al. Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications. Crit Care Med. 1999;27(4):733–740. doi: 10.1097/00003246-199904000-00026. [DOI] [PubMed] [Google Scholar]
  • 34.Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–638. doi: 10.1038/nri.2016.90. [DOI] [PubMed] [Google Scholar]
  • 35.Wu H, Lai CF, Chang-Panesso M, Humphreys BD. Proximal tubule translational profiling during kidney fibrosis reveals proinflammatory and long noncoding RNA expression patterns with sexual dimorphism. J Am Soc Nephrol. 2020;31(1):23–38. doi: 10.1681/ASN.2019040337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Dolsen MR, Crosswell AD, Prather AA. Links between stress, sleep, and inflammation: are there sex differences? Curr Psychiatry Rep. 2019;21(2):8. doi: 10.1007/s11920-019-0993-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Slominski B, Skrzypkowska M, Ryba-Stanislawowska M, Brandt A. Sex-related association of serum uric acid with inflammation, kidney function and blood pressure in type 1 diabetic patients. Pediatr Diabetes. 2018;19(5):1014–1019. doi: 10.1111/pedi.12670. [DOI] [PubMed] [Google Scholar]
  • 38.Ichii O, Nakamura T, Irie T, et al. Close pathological correlations between chronic kidney disease and reproductive organ-associated abnormalities in female cotton rats. Exp Biol Med (Maywood) 2018;243(5):418–427. doi: 10.1177/1535370218758250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Dogra G, Irish A, Chan D, Watts G. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis. 2006;48(6):926–934. doi: 10.1053/j.ajkd.2006.08.008. [DOI] [PubMed] [Google Scholar]
  • 40.Bernelot Moens SJ, Verweij SL, van der Valk FM, et al. Arterial and cellular inflammation in patients with CKD. J Am Soc Nephrol. 2017;28(4):1278–1285. doi: 10.1681/ASN.2016030317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Xie J, Lv J, Wang W, et al. Kidney failure risk prediction equations in IgA nephropathy: a multicenter risk assessment study in Chinese patients. Am J Kidney Dis. 2018;72(3):371–380. doi: 10.1053/j.ajkd.2018.01.043. [DOI] [PubMed] [Google Scholar]
  • 42.Zhu B, Liu WH, Yu DR, et al. The association of low hemoglobin levels with IgA nephropathy progression: a two-center cohort study of 1,828 Cases. Am J Nephrol. 2020;51(8):624–634. doi: 10.1159/000508770. [DOI] [PubMed] [Google Scholar]
  • 43.Chen T, Xia E, Chen T, et al. Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy. EBioMedicine. 2020;52:102657. doi: 10.1016/j.ebiom.2020.102657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Rauen T, Fitzner C, Eitner F, et al. Effects of two immunosuppressive treatment protocols for IgA nephropathy. J Am Soc Nephrol. 2018;29(1):317–325. doi: 10.1681/ASN.2017060713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Jefferson JA. Complications of immunosuppression in glomerular disease. Clin J Am Soc Nephrol. 2018;13(8):1264–1275. doi: 10.2215/CJN.01920218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Floege J, Rauen T. Immunosuppression in IgA nephropathy: how certain are we? Kidney Int. 2016;89(1):9–11. doi: 10.1016/j.kint.2015.11.013. [DOI] [PubMed] [Google Scholar]
  • 47.Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225–2236. doi: 10.1056/NEJMoa1415463. [DOI] [PubMed] [Google Scholar]
  • 48.Avramovski P, Avramovska M, Sotiroski K, Sikole A. Acute-phase proteins as promoters of abdominal aortic calcification in chronic dialysis patients. Saudi J Kidney Dis Transplant. 2019;30(2):376–386. doi: 10.4103/1319-2442.256845. [DOI] [PubMed] [Google Scholar]

Articles from International Urology and Nephrology are provided here courtesy of Springer

RESOURCES